Latest Regulatory Filings News

CLINUVEL Pharmaceuticals is preparing to elevate its American Depository Receipt program to a Nasdaq Level II listing by the end of 2025, aiming to enhance visibility and trading access in the U.S. without altering its primary ASX listing.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

Platinum Asia Investments Limited (PAI) shares have been suspended following Federal Court approval of a scheme exchanging all shares for units in the Platinum Asia Fund Complex ETF (PAXX). This marks a significant structural shift for PAI investors.

Lumos Diagnostics has submitted its CLIA waiver application for FebriDx® to the FDA, backed by strong clinical data and triggering significant milestone payments. Approval could expand the U.S. market opportunity fifteen-fold to over $1 billion.

Pinnacle Minerals Limited’s PIMOA securities have been suspended from ASX quotation due to non-compliance with key listing rules, raising questions about the company’s regulatory standing.

Cobre Limited’s CBEO securities have been suspended from ASX quotation due to non-compliance with key listing rules, raising questions about the company’s regulatory standing.

Sayona Mining’s merger with Piedmont Lithium faces further delay due to shareholder quorum shortfall, prompting an extension of its financing agreement with Resource Capital Fund VIII. The extension includes a potential AU$38 million capital injection through new options.

The Supreme Court of New South Wales has approved DP World Australia’s acquisition of Silk Logistics, paving the way for a $2.14 per share cash payout to Silk shareholders and imminent suspension of Silk shares on the ASX.

Domain Holdings Australia has updated its announcement to correct the lodgement date of court orders critical to its special dividend tied to the CoStar acquisition scheme.

Memphasys Limited has submitted its Felix™ sperm separation system for CE Mark approval, targeting Europe’s $5 billion IVF market, while expanding direct sales in Japan and validating its RoXsta™ oxidative stress diagnostic platform.

Vonex Limited has taken a key step in its acquisition by Maxo Telecommunications, lodging a draft Scheme Booklet with ASIC that includes an independent expert’s report. This move brings the proposed takeover closer to shareholder approval and regulatory clearance.

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.